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ABSTRACT
Purpose. Hormone receptor-positive (HR?) tumors have
heterogeneous biology and present a challenge for deter-
mining optimal treatment. In the Neoadjuvant Breast
Registry Symphony Trial (NBRST) patients were classified
according to MammaPrint/BluePrint subtyping to provide
insight into the response to neoadjuvant endocrine therapy
(NET) or neoadjuvant chemotherapy (NCT).
Objective. The purpose of this predefined substudy was to
compare MammaPrint/BluePrint with conventional ‘clini-
cal’ immunohistochemistry/fluorescence in situ hybridiza-
tion (IHC/FISH) subtyping in ‘clinical luminal’ [HR?/
human epidermal growth factor receptor 2-negative
(HER2-)] breast cancer patients to predict treatment
sensitivity.
Methods. NBRST IHC/FISH HR?/HER2- breast cancer
patients (n = 474) were classified into four molecular
subgroups by MammaPrint/BluePrint subtyping: Luminal
A, Luminal B, HER2, and Basal type. Pathological complete
response (pCR) rates were compared with conventional IHC/
FISH subtype.
Results. The overall pCR rate for ‘clinical luminal’
patients to NCT was 11 %; however, 87 of these 474
patients were reclassified as Basal type by BluePrint, with a
high pCR rate of 32 %. The MammaPrint index was highly
associated with the likelihood of pCR (p\ 0.001). Fifty-
three patients with BluePrint Luminal tumors received
NET with an aromatase inhibitor and 36 (68 %) had a
clinical response.
Conclusions. With BluePrint subtyping, 18 % of clinical
‘luminal’ patients are classified in a different subgroup,
compared with conventional assessment, and these patients
have a significantly higher response rate to NCT compared
with BluePrint Luminal patients. MammaPrint/BluePrint
subtyping can help allocate effective treatment to appro-
priate patients. In addition, accurate identification of subtype
biology is important in the interpretation of neoadjuvant
treatment response since lack of pCR in luminal patients
does not portend the worse prognosis associated with
residual disease in Basal and HER2 subtypes.
The Neoadjuvant Breast Registry Symphony Trial
(NBRST) is a prospective, phase IV registry study where
neoadjuvant chemotherapy (NCT) and neoadjuvant endo-
crine therapy (NET) regimen outcomes are evaluated, both
as response to treatment at the time of surgery and longer
term at 5 years.1 Since tumors are classified by gene
expression array with the molecular subtyping profile
BluePrint as well as the MammaPrint prognostic profile,
 The Author(s) 2016. This article is published with open access
at Springerlink.com
First Received: 20 June 2016;
Published Online: 21 October 2016
P. Whitworth, MD
e-mail: patwhitworth@gmail.com
Ann Surg Oncol (2017) 24:669–675
DOI 10.1245/s10434-016-5600-x
response to treatment according to conventional clinical
versus molecular classification can be compared. Phase IV
studies are important because they document outcomes after
new technology becomes widely available in clinical prac-
tice. Although phase III randomized trials are usually
required to make major changes in practice (with some
emerging possible exceptions, such as basket trials), phase IV
experience often supports refined applications for approved
technology and can generate important new hypotheses.
The NBRST has enrolled over 1000 patients at a time
when the treatment of patients in the neoadjuvant setting
has become standard, not only for large inoperable breast
cancer that may become operable by downstaging but also
for earlier-stage cancer providing a personalized measure
of effectiveness against the actual tumor in the individual
patient. The NBRST provided physicians and patients with
molecular prognostic information to potentially guide
treatment allocation and provide a molecular understanding
of response to treatment or lack thereof.
Hormone receptor-positive (HR?)/human epidermal
growth factor receptor 2-negative (HER2-) tumors remain a
challenge for determining best treatment, especially since a
subset has substantial benefit with chemotherapy. The 2015
St. Gallen Expert Consensus considers NET the preferred
treatment for Luminal A-type postmenopausal patients.2
Endocrine therapy can also have an important role in the
neoadjuvant setting where systemic treatment may be indi-
cated for several months prior to surgery in postmenopausal
women with large and/or technically inoperable tumors. This
treatment is intended to shrink the tumor so that in locally
advanced disease surgery becomes possible, and in large
operable breast cancers breast-conserving surgery can be
performed.3,4 However, large, prospective, randomized,
neoadjuvant trials in HR? patients with NET are still in
progress. Response to treatment is more difficult to define in
HR? breast cancer patients; pathological complete response
(pCR) is less likely to occur in the first place, and it is not a
surrogate endpoint for survival in these patients.5 More
importantly, no robust formal definition of meaningful
response to NET is available. Quantitative measurements of
response rely on indirect assessments. While ‘clinical
response’ refers to the decrease in tumor size, ‘pathological
response’ can detect a meaningful decrease in tumor cellu-
larity with an increase in fibrosis or formation of fibrous
connective tissue. More complications arise from cases
where these definitions are discordant in approximately
20 % of tumors.6 Physicians still rely on clinical response
during treatment in daily practice.
Functional molecular subtyping with the 80-gene
BluePrint assay and 70-gene MammaPrint assay was
developed to improve biological identification for better
treatment assignment (to responsive patients), and further
dissection of patient groups wherein additional treatment
options should be evaluated in future trials. Identification
of a group of patients where NET is effective can avoid
unnecessary toxicity when the same group is minimally
responsive to chemotherapy. BluePrint subtyping classifies
patients into the following subgroups: Luminal, HER2, and
Basal type. The group of genes identifying Luminal-type
breast cancer is highly enriched for genes having an
estrogen receptor (ER) binding site proximal to the pro-
moter region, suggesting that these genes are direct targets
of the ER.7 MammaPrint combined with BluePrint can
substratify luminal subtype patients into Luminal A and
Luminal B groups. MammaPrint has recently provided
level 1A evidence for identification of patients with low
recurrence risk and negligible chemotherapy benefit,8 and
BluePrint molecular subgroups had distinctly different
outcomes in retrospective analyses from four NCT trials.
Luminal A patients have a low pCR rate of 6 % to NCT
and an excellent distant metastasis survival of 93 %.9
The NBRST trial results allow us to determine if
physicians and patients incorporate such findings in daily
clinical practice, and help answer important practical
questions such as how often do physicians choose NET in
clinical luminal patients, and is there a difference in clin-
ical characteristics for patients who receive NCT versus
NET. The NBRST also documents the molecular subtype
for clinical luminal patients, the pCR rate to NCT and the
clinical response to NET in these different molecular
subtypes, and correlates MammaPrint results in luminal
patients with pCR to chemotherapy.
PATIENTS AND METHODS
Patients
Patients with breast cancer from 62 US institutions who
had started, or were scheduled to start, NCT or neoadjuvant
hormone therapy, after successful MammaPrint/BluePrint
assay, were enrolled in the prospective NBRST registry
trial between June 2011 and November 2014. Patients with
T4 or inflammatory disease were eligible for inclusion.
Excluded from the study were patients who had an exci-
sional biopsy or axillary dissection, confirmed distant
metastatic disease, any prior chemotherapy, radiotherapy,
or endocrine therapy for the treatment of breast cancer and
any serious uncontrolled intercurrent infections or other
serious uncontrolled comorbid disease. The trial was
approved by Institutional Review Boards in all participat-
ing centers, and was registered with ClinicalTrials.gov
(identifier NCT01479101). Before registration, all patients
provided signed informed consent for the trial and for
research on their tumor samples. Treatment was at the
discretion of the physician adhering to either National
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Comprehensive Cancer Network (NCCN)-approved regi-
mens or other peer-reviewed established regimens. No
specific recommendations were given for the selection to
treat patients with neoadjuvant treatment. The NBRST
registry is a unique, large database of US patients in a wide
variety of clinical practice settings that provides insight
into outcomes associated with molecular tumor type and
systemic treatment for this neoadjuvant treatment-eligible
population. For the current substudy, only locally assessed
immunohistochemistry/fluorescence in situ hybridization
(IHC/FISH) HR? , HER2- patients were included.
Molecular and Clinical Characteristics
The 70-gene expression profile MammaPrint and the
80-gene molecular subtyping profile BluePrint were assessed
from the fresh or formalin-fixed core needle biopsy at the
centralized Agendia Laboratory blinded for clinical and
pathological data. Microarray analysis (RNA labeling,
microarray hybridization, and scanning) was performed on the
RNA, which was cohybridized with a standard reference to the
custom-designed diagnostic chip, each containing oligonu-
cleotide probes for the profiles in triplicate or more.7,10
Four distinct molecular subgroups —Luminal A type,
Luminal B type, HER2 type, and Basal type—were iden-
tified and used for further analysis. In this study, we
defined Luminal A-type tumors as Luminal type by Blue-
Print with a low risk score by MammaPrint, and Luminal
B-type tumors as BluePrint Luminal type with a Mam-
maPrint high risk score.
HR status (ER and progesterone receptor [PR] status)
and HER2 status were determined locally on pretreatment
core biopsies. Both ER and PR status were determined by
IHC and were considered positive if there was C1 %
positive staining.
Objectives and Endpoints
The primary endpoint for patients who received NCT was
pCR, which is defined as the absence of invasive carcinoma
in both the breast and axilla at microscopic examination of
the resection specimen, regardless of the presence of carci-
noma in situ (ypT0/isN0). All pCRs were verified with a de-
identified copy of the surgical pathology report.
The primary objective for patients who received NET
was clinical response rate, which was defined as the pro-
portion of patients who achieved a complete or partial
response at any time before surgery.
Tumor assessments at baseline, before surgery, at the
final visit, or at withdrawal were carried out by magnetic
resonance imaging (MRI), ultrasound, mammography,
clinical breast examination (CBE), or other conventional
methods as per local practice.
Statistical Analysis
Baseline characteristics, including age, menopausal
status, ER/PR status, T stage, grade, nodal involvement and
histology, as well as MammaPrint and BluePrint results
were summarized in an incidence table. This exploratory
analysis was undertaken for both neoadjuvant treatment
groups (NCT and NET). A v2 test was performed for
comparison of a categorical variable between both treat-
ment groups, and Fisher’s exact test was used when a cell
contained\5. A non-parametric test was used to compare
medians of the continuous variables. A significant finding
was defined as a p value below 0.05.
Univariate logistic regression analyses of pCR to NCT
were evaluated to identify individual patient and tumor
prognostic factors. Significant factors from the univariate
analyses were included in a multivariate modeling proce-
dure. The probability of pCR as a function of the
MammaPrint index was calculated. All calculations were
performed using IBM SPSS Statistics 22.0 (IBM Corpo-
ration, Armonk, NY, USA).
RESULTS
A total of 474 eligible patients with IHC/FISH HR?/
HER2- tumors were enrolled in the NBRST study.
MammaPrint classified 29 % of patient samples as low risk
and 71 % as high risk, while BluePrint classified 29 % of
patient samples as Luminal A type, 53 % as Luminal B
type, and 18 % as Basal type.
Overall, 405 patients were treated with NCT, 61 were
treated with NET, and 8 received both NCT and NET.
Table 1 lists the pretreatment patient and tumor charac-
teristics for the NCT and NET groups.
Patients in the NCT group were, on average, 20 years
younger, and 50 % were premenopausal. NCT patients had
more positive lymph nodes (63 vs. 26 %; p\ 0.001) and
had a breast cancer with a higher histological grade (grade
3: 47 % vs. 10 %; p\ 0.001).
Patients treated with NCT more often had a high-risk
profile according to MammaPrint, compared with patients
treated with NET (77 vs. 67 %; p\ 0.001), which resulted
in a higher amount/number of patients with Luminal B
tumors within the NCT group (55 vs. 31 %). According to
BluePrint, one-fifth of the NCT group was Basal type.
Neoadjuvant Chemotherapy
Review of the chemotherapy regimens showed that the
most commonly used regimen was AC-T (doxoru-
bicin/cyclophosphamide followed by a taxane) or
TAC (docetaxel/doxorubicin/cyclophosphamide) [43 %],
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followed by dose dense AC-T (28 %), and TC (doc-
etaxel/cyclophosphamide) [16 %].
Overall, 46 (11 %) patients did not complete all planned
NCT cycles. Two patients died during NCT (septicemia
and encephalitis infection), 29 stopped early because of
toxicities, 7 stopped early because of tumor progression or
lack of response, 3 patients and 1 medical oncologist
decided to proceed to surgery before completion of all
cycles, and no reason was specified for the remaining 4
patients.
The overall pCR (ypT0/isN0) rate to NCT was 11 %.
Only 2 of 95 (2 %) patients with a MammaPrint low-risk
tumor had a pCR, while significantly more patients with
high-risk tumors had a pCR (13 %; p = 0.001). Figure 1
shows how the MammaPrint index was highly associated
with the likelihood of pCR (p\ 0.001), suggesting that
patients with tumor samples at highest risk of recurrence
are more likely to have chemotherapy benefit.
The pCR rate for the BluePrint Luminal subtype was
only 5 %, and statistically significantly less than the pCR
TABLE 1 Pre-treatment clinical characteristics and treatment regimens (n = 466a, HR?/HER2-)
NCT (n = 405) NET (n = 61) p value
Median age, years (range) 51 (22–79) 71 (43–88) \0.001
Pre- and perimenopausalb 196 (48) 5 (8) \0.001
Postmenopausalc 209 (52) 56 (92)
T1/T2 268 (66) 47 (77) 0.091
T3/T4 137 (34) 14 (23)
Clinically LN? 254 (63) 16 (26) \0.001
Grade 1/2 197 (49) 51 (84) \0.001
Grade 3 190 (47) 6 (10)
Grade unknown 18 (4) 4 (7)
Invasive ductal carcinoma 336 (83) 43 (70) 0.001
Invasive lobular carcinoma 46 (11) 17 (28)
Other 23 (6) 1 (2)
ER status (IHC)? 388 (96) 61 (100) 0.146
PR status (IHC)? 316(78) 54 (89) 0.063
MammaPrint low risk 95 (23) 20 (33)
MammaPrint high risk 310 (77) 41 (67)
BluePrint Luminal A type 95 (23) 41 (67)
BluePrint Luminal B type 224 (55) 19 (31)
BluePrint HER2 type 1 (\1) –
BluePrint Basal type 85 (21) 1 (2)
AC-T or TAC 175 (43) –
ddAC—T 113 (28) –
TC 65 (16) –
AC 16 (4) –
Other NCT regimen 36 (9) –
Anastrozole – 34 (56)
Letrozole – 15 (25)
Tamoxifen – 7 (11)
Exemestane – 2 (3)
Other 3 (5)
Significant values are given in bold at p B 0.05
Data are expressed as n (%) unless otherwise specified
a 8 Patients had NCT and NET
b Pre- and perimenopausal: 6–12 months since last menstrual period
c Postmenopausal:[12 months since last menstrual period or bilateral oophorectomy/hysterectomy
ER estrogen receptor, PR progesterone receptor, IHC immunohistochemistry, A doxorubicin, T taxane, C cyclophosphamide, HR? hormone
receptor-positive, HER2- human epidermal growth factor receptor 2-negative, LN ? lymph node-positive, NCT neoadjuvant chemotherapy,
NET neoadjuvant endocrine therapy
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rate of 32 % for the 85 clinical IHC/FISH HR?/
HER2- patient samples classified as Basal subtype
(p\ 0.001) (Fig. 2).
The following factors were found to be significantly
(p\ 0.05) associated with the odds of achieving pCR
based on univariate logistic regression analyses (see
Table 2): tumor grade, PR status, MammaPrint result, and
BluePrint result. In addition, the following factors were
independently associated with the odds of achieving pCR
based on multivariate logistic regression modeling: Blue-
Print (p = 0.005) and grade (p = 0.045).
Neoadjuvant Endocrine Therapy
Overall, 34 of 69 NET patients (56 %) received anas-
trozole as NET, followed by letrozole (n = 15, 25 %) and
tamoxifen (n = 7, 11.5 %) (Table 3).
All but one patient had a BluePrint Luminal tumor. One
patient had a BluePrint Basal-type tumor and this patient
progressed on letrozole followed by exemestane.
Fifty-three patients with BluePrint Luminal tumors
received NET with an aromatase inhibitor and 36 (68 %)
had a clinical response (Fig. 3). Seven patients received
tamoxifen as NET and two (29 %) had a clinical response.
Patients with Luminal A tumors (MammaPrint Low Risk)
had the same clinical response rate (68.6 %; 24/35) to NET
as patients with Luminal B (MammaPrint high risk) tumors
(66.7 %; 12/18).
Surgery
Overall, 99 % of enrolled patients underwent surgery;
39 % had a lumpectomy or segmental resection and 61 %
had a mastectomy. Patients who were treated with NET
FIG. 1 Probability of pCR
(ypT0/isN0) to NCT for the
MammaPrint index (n = 405),
and probability of pCR as a
function of the MammaPrint
index. The red and grey circles
represent patients who did and
did not have a pCR,
respectively. The MammaPrint
index is positively associated
with the likelihood of pCR
(p\ 0.001), suggesting that
patients who are at the highest
risk of recurrence are more




FIG. 2 Chemosensitivity (pCR) per subtype classification
(n = 403). One patient was classified as HER2 type, but this patient
did not have a pCR. pCR pathological complete response, HER2
human epidermal growth factor receptor, BP BluePrint, HR? hor-
mone receptor-positive, IHC immunohistochemistry, FISH
fluorescence in situ hybridization
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had a lumpectomy or segmental resection rate of 52.5 %
(32/61), which is significantly higher than the 37 % rate in
patients who received NCT (p = 0.0098).
DISCUSSION
In the prospective neoadjuvant NBRST study, 405
(85 %) patients with HR?/HER2- tumors received NCT,
and the overall pCR (ypT0/is/N0) rate was 11 %. Only 2 of
95 (2 %) patients with MammaPrint low-risk tumors had a
pCR, while significantly more patients with high-risk
tumors had a pCR (13 %; p = 0.001). The MammaPrint
index was highly associated with the likelihood of pCR
(p\ 0.001), suggesting that patients with tumors at the
highest risk of recurrence are more likely to have
chemotherapy benefit.
TABLE 2 Univariate and multivariate analysis of patient and tumor characteristics associated with pCR (ypT0/isN0) (n = 405)
Characteristic Univariate OR (95 % CI) Univariate p value Multivariate OR (95 % CI) Multivariate p value
Age 0.985 (0.959–1.012) 0.276
Menopausal status 1.396 (0.739–2.638) 0.304
cT stage 0.486 (0.226–1.045) 0.065
c Lymph nodes 0.723 (0.381–1.369) 0.319
Grade 6.353 (2.75–14.675) 0.000 2.615 (1.009–6.777) 0.048
Histology 0.334 (0.078–1.431) 0.140
ER 0.891 (0.197–4.037) 0.881
PR 0.171 (0.088–0.331) 0.000 0.479 (0.216–1.063) 0.070
MammaPrint 7.140 (1.694–30.101) 0.007 1.922 (0.420–9.438) 0.385
BluePrint-subtype 8.758 (4.440–17.273) 0.000 3.301 (1.422–7.666) 0.005
Significant values are given in bold at p B 0.05
pCR pathological complete response, OR odds ratio, CI confidence interval, ER estrogen receptor, PR progesterone receptor
FIG. 3 Clinical response rate (cCR and PR) to neoadjuvant endocrine therapy with an aromatase inhibitor in BluePrint Luminal tumors
(n = 53). cCR clinical complete response, PR partial response
TABLE 3 Clinical response and duration to the neoadjuvant endocrine therapy regimens
Regimen N (%) Mean duration (weeks) Clinical response determined by physician (n)
CR PR SD PD
Anastrozole (A) 34 (56) 29 (4–83) 1 22 11 –
Letrozole (L) 15 (22) 25 (7–69) – 10 4 1
Exemestane (E) 2 (3) 46 (35–57) 1 1 – –
Letrozole ? exemestane 2 (3) 27 (17–36) – – 1 1a
Anastrozole ? exemestane 1 (2) 26 – 1 – –
Tamoxifen 7 (10) 26 (4–74) – 2 5 –
CR complete response, PR partial response, SD stable disease, PD progressive disease
a BluePrint Basal-type patient
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BluePrint functional subtyping revealed that 18 % of
patients with locally assessed HR?/HER2- tumors were
BluePrint Basal type, with a significantly higher response
rate of 32 % compared with the 5 % of BluePrint Luminal-
type cases. Multivariate logistic regression showed that
BluePrint and grade were found to be significantly asso-
ciated with the odds of achieving pCR. This confirms, in a
wide range of practice settings, the approximately 1-in-5
reclassification rate for ‘clinical luminal’ tumors that has
been previously described for BluePrint,1 as well as by
others.11 Molecular classification of these tumors indicates
a Basal-type make-up despite positive ER staining. These
tumors may lack a functional response to estrogen and
consequently respond more like triple-negative tumors,
therefore benefit from chemotherapy for these patients
should be considered likely.
Patients with a true Luminal-type tumor can be good
candidates for NET. The current study included 53 patients
with BluePrint Luminal tumors who received NET with an
aromatase inhibitor. Of these 53 patients, 36 (68 %) had a
clinical response. Patients with this tumor type do not
demonstrate the correlation between disease-free survival
and pCR seen with Basal and HER2 types. In fact, those
with Luminal A type have an excellent prognosis in spite of
their low pCR rate.8 These findings are also in accord with
the recently reported prospective, randomized, phase III
study MINDACT, which evaluated 6693 women with stage
T1–T3 operable breast cancer with 0–3 nodes involved, in
which 64 % of women had a MammaPrint low risk of
recurrence. These patients (including 48 % with positive
nodes) had a 5-year distant metastases-free survival of
95 %, irrespective of the use of adjuvant chemotherapy.7
CONCLUSION
MammaPrint and BluePrint reclassify 18 % (87/474) of
patients compared with conventional assessment (1
HER2-type patient and 86 Basal-type patients). These
patients have a significant higher response rate to NCT
compared with BluePrint Luminal patients, while Blue-
Print Luminal patients have an excellent partial response
rate to NET.
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